Euretos presents groundbreaking drug target validation approach

Euretos has been selected to speak at the Target Validation using Genomics and Informatics conference from 4-6 December, organised by EMBL, Europe’s flagship laboratory for the life sciences.The topic of the Euretos presentation will be the groundbreaking work on target discovery which Euretos also presented at the ECCB in September of this year. In particular the Euretos Analytics application will be presented. The conference brings together a balanced mix of academic researchers, pharma & biotech scientists and technology providers. 

The ability to guide researchers to discover novel therapeutic targets or biomarkers is regularly confirmed through recent scientific discoveries in various disease areas, such as: breast cancer, pancreatic cancer, chronic kidney disease and traumatic brain injury.

“We are very honoured to have been selected to present at this unique event organised by EMBL”, says Aram Krol, Head of Product Management at Euretos. “It is an especially interesting event as academic and industry partners are equally represented. We have strong evidence that our target identification scoring model is highly effective in predicting suitable drug targets and will be presenting especially on the progress we have made in this area”.

About EMBL

Founded in 1974, EMBL is Europe’s flagship laboratory for the life sciences – an intergovernmental organisation with more than 80 independent research groups covering the spectrum of molecular biology. It operates across five sites: Heidelberg, Hamburg, Grenoble, Monterotondo and EMBL-EBI Hinxton.

Euretos Newsletter

Subscribe to our mailing list and receive our quarterly updates!

Data-driven disease insights